ABS Direct Equity Fund LLC Makes New $3.44 Million Investment in Cellebrite DI Ltd. $CLBT

ABS Direct Equity Fund LLC purchased a new stake in Cellebrite DI Ltd. (NASDAQ:CLBT) in the first quarter, HoldingsChannel reports. The firm purchased 250,000 shares of the company’s stock, valued at approximately $3,445,000. Cellebrite DI makes up approximately 2.7% of ABS Direct Equity Fund LLC’s holdings, making the stock its 12th largest position.

Several other institutional investors have also made changes to their positions in the stock. Towarzystwo Funduszy Inwestycyjnych PZU SA increased its stake in Cellebrite DI by 81.0% during the 4th quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock worth $34,000 after acquiring an additional 850 shares during the period. Advisory Services Network LLC acquired a new position in Cellebrite DI in the third quarter valued at about $40,000. CWM LLC raised its stake in Cellebrite DI by 57.0% in the fourth quarter. CWM LLC now owns 2,449 shares of the company’s stock valued at $44,000 after purchasing an additional 889 shares in the last quarter. First Horizon Corp lifted its position in Cellebrite DI by 421.8% during the fourth quarter. First Horizon Corp now owns 2,891 shares of the company’s stock worth $52,000 after purchasing an additional 2,337 shares during the period. Finally, Vestcor Inc bought a new stake in Cellebrite DI during the third quarter worth about $70,000. 45.88% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

CLBT has been the topic of several recent analyst reports. DA Davidson started coverage on shares of Cellebrite DI in a report on Wednesday, May 27th. They issued a “buy” rating and a $20.00 target price on the stock. Needham & Company LLC dropped their target price on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Finally, Weiss Ratings raised shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 18th. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $21.40.

Cellebrite DI Stock Performance

Cellebrite DI stock opened at $14.22 on Monday. Cellebrite DI Ltd. has a 52 week low of $11.02 and a 52 week high of $19.98. The stock has a market capitalization of $3.55 billion, a P/E ratio of 50.79, a price-to-earnings-growth ratio of 1.76 and a beta of 1.17. The stock has a fifty day moving average of $14.19 and a 200-day moving average of $14.28.

Insider Buying and Selling at Cellebrite DI

In other Cellebrite DI news, CEO Thomas E. Hogan sold 103,188 shares of Cellebrite DI stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $15.76, for a total value of $1,626,242.88. Following the transaction, the chief executive officer owned 590,777 shares in the company, valued at $9,310,645.52. The trade was a 14.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO David Barter sold 41,734 shares of the business’s stock in a transaction dated Wednesday, July 8th. The stock was sold at an average price of $16.38, for a total value of $683,602.92. Following the transaction, the chief financial officer directly owned 334,219 shares of the company’s stock, valued at approximately $5,474,507.22. The trade was a 11.10% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 158,191 shares of company stock worth $2,479,438 over the last 90 days. Insiders own 5.70% of the company’s stock.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.